medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»medalphabet-186Research ArticleСтатьиАнтидепрессанты в профилактике мигрениAntidepressants in prevention of migraineМакаровС. А.MakarovS. A.noemail@neicon.ruФилатоваЕ. Г.FilatovaE. G.noemail@neicon.ruФГАОУ ВО «Первый Московский государственный медицинский университет имени И. М. Сеченова (Сеченовский университет)» Минздрава РоссииРоссияFirst Moscow State Medical University n.a. I. M. SechenovRussian Federation201716052017215Неврология и психиатрия3340Copyright © Макаров С.А., Филатова Е.Г., 20172017Макаров С.А., Филатова Е.Г.Makarov S.A., Filatova E.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/186

В обзоре представлена современная информация о хронической мигрени и её лечении при помощи антидепрессантов. Обсуждаются механизмы анальгетического действия антидепрессантов. Подробно излагаются материалы об эффективности отдельных представителей антидепрессантов разных групп. Рассматриваются национальные рекомендации по лечению хронической мигрени в разных странах (Соединенных Штатах Америки, Европе, России).

The review presents current information on chronic migraine and its treatment with antidepressants. The mechanisms of analgesic action of antidepressants are discussed. Details of the effectiveness of individual representatives of antidepressants of different groups. National recommendations on chronic migraine treatment in different countries (United States of America, Europe, Russia) are considered

антидепрессантыхроническая мигреньantidepressantschronic migraineReferencesBuse DC, Manack AN, Fanning KM, et al. Chronic migraine prevalence, disability, and sociodemographic factors: Results from the American Migraine Prevalence and Prevention Study. Headache 2012; 52: 1456-1470.Buse DC, Manack AN, Fanning KM, et al. Chronic migraine prevalence, disability, and sociodemographic factors: Results from the American Migraine Prevalence and Prevention Study. Headache 2012; 52: 1456-1470.Куцемелов И. Б., Табеева Г. Р. Эпидемиология первичных головных болей. Боль, 2004; 4 (5): 25-31.Куцемелов И. Б., Табеева Г. Р. Эпидемиология первичных головных болей. Боль, 2004; 4 (5): 25-31.Осипова В. В. Головные боли. В: Боль (практическое руководство для врачей) / Под редакцией Н. Н. Яхно, М. Л. Кукушкина. М.: Издательство РАМН, 2011. 512 с.Осипова В. В. Головные боли. В: Боль (практическое руководство для врачей) / Под редакцией Н. Н. Яхно, М. Л. Кукушкина. М.: Издательство РАМН, 2011. 512 с.Артеменко А. Р., Куренков А. Л., Антипова О. С. Диагностика и лечение хронической мигрени. Москва, Горячая линия - Телеком, 2014, 206 с.Артеменко А. Р., Куренков А. Л., Антипова О. С. Диагностика и лечение хронической мигрени. Москва, Горячая линия - Телеком, 2014, 206 с.Blumenfeld A., Varon S., Wilcox T., Buse D., Kawata A., Manack A., Lipton R. (2010). Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS). Cephalalgia, 31 (3), 301-315.Blumenfeld A., Varon S., Wilcox T., Buse D., Kawata A., Manack A., Lipton R. (2010). Disability, HRQoL and resource use among chronic and episodic migraineurs: Results from the International Burden of Migraine Study (IBMS). Cephalalgia, 31 (3), 301-315.Silberstain SD, Holland S, Freitag F, et al. Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Report of the Quality Standarts Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012; 78: 1337-1345.Silberstain SD, Holland S, Freitag F, et al. Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults: Report of the Quality Standarts Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012; 78: 1337-1345.Colombo B, Annovazzi PO, Comi G. Therapy of primary headaches: the role of antidepressants. Neurol. Sci. 2004 Oct; 25 Suppl. 3: S 171-5.Colombo B, Annovazzi PO, Comi G. Therapy of primary headaches: the role of antidepressants. Neurol. Sci. 2004 Oct; 25 Suppl. 3: S 171-5.Antonaci F, Dumitrache C, De Cillis I, Allena M. A review of current European treatment guidelines for migraine. The Journal of Headache and Pain. 2010; 11 (1): 13-19.Antonaci F, Dumitrache C, De Cillis I, Allena M. A review of current European treatment guidelines for migraine. The Journal of Headache and Pain. 2010; 11 (1): 13-19.Клинические рекомендации «Мигрень у взрослых». Доступно по: http://cr.rosminzdrav.ru/ schema.html?id = 199#/text. Ссылка активна на 11.04.17.Клинические рекомендации «Мигрень у взрослых». Доступно по: http://cr.rosminzdrav.ru/ schema.html?id = 199#/text. Ссылка активна на 11.04.17.Dimatteo MR. Variations in patients’ adherence to medical recommendations: A quantitative review of 50 years of research. Med. Care 2004; 42:200-209.Dimatteo MR. Variations in patients’ adherence to medical recommendations: A quantitative review of 50 years of research. Med. Care 2004; 42:200-209.Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015 May; 35 (6): 478-88.Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015 May; 35 (6): 478-88.Вейн А. М., Вонесенская Т. Г., Голубев В.Л., Дюкова Г. М. Депрессия в неврологической практике. 3-е издание. МИА. Москва. 2007197 с.Вейн А. М., Вонесенская Т. Г., Голубев В.Л., Дюкова Г. М. Депрессия в неврологической практике. 3-е издание. МИА. Москва. 2007197 с.Latisheva N., Kurenkov A., Filatova E. Evidence of persistent central sensitization in chronic headaches: a muti-metod study J. Headache Pain 2008, N9, p. 295-300.Latisheva N., Kurenkov A., Filatova E. Evidence of persistent central sensitization in chronic headaches: a muti-metod study J. Headache Pain 2008, N9, p. 295-300.Stahl’s essential psychopharmacology: neuroscientific basis and practical application / Stephen M. Stahl; with illustrations by Nancy Muntner. 4th ed.Stahl’s essential psychopharmacology: neuroscientific basis and practical application / Stephen M. Stahl; with illustrations by Nancy Muntner. 4th ed.Silberstein SD, Goadsby PJ. Migraine: preventive treatment. Cephalalgia 2002; 22: 491-512.Silberstein SD, Goadsby PJ. Migraine: preventive treatment. Cephalalgia 2002; 22: 491-512.Tawio YO, Levine JD. Furterconfirmation of the role of adenyl cyclase and of cAMF-depent protein kinase in primary afferent hyperalgesia. Neuroscience 44: 131-135.Tawio YO, Levine JD. Furterconfirmation of the role of adenyl cyclase and of cAMF-depent protein kinase in primary afferent hyperalgesia. Neuroscience 44: 131-135.Smith H., C., G. McCleane. Antidepressants as Analgesics. Practical Management of Pain, 38, 530-542.e4.Smith H., C., G. McCleane. Antidepressants as Analgesics. Practical Management of Pain, 38, 530-542.e4.Gray RN, Goslin RE, McCrory DC, Eberlein K, Tulsky J, Hasselblad V. Drug Treatments for the Prevention of Migraine Headache. Rockville (MD): Agency for Health Care Policy and Research (US); 1999 Feb.Gray RN, Goslin RE, McCrory DC, Eberlein K, Tulsky J, Hasselblad V. Drug Treatments for the Prevention of Migraine Headache. Rockville (MD): Agency for Health Care Policy and Research (US); 1999 Feb.Jackson JL, Shimeall W, Sessums L, Dezee KJ, Becher D, Diemer M, Berbano E, O'Malley PG. Tricyclic antidepressants and headaches: systematic review and meta-analysis. BMJ. 2010 Oct20; 341: c5222.Jackson JL, Shimeall W, Sessums L, Dezee KJ, Becher D, Diemer M, Berbano E, O'Malley PG. Tricyclic antidepressants and headaches: systematic review and meta-analysis. BMJ. 2010 Oct20; 341: c5222.Magyar M, Csépány É, Gyüre T, Bozsik G, Bereczki D, Ertsey C. Tricyclic antidepressant therapy in headache. Neuropsychopharmacol. Hung. 2015 Dec; 17 (4): 177-82.Magyar M, Csépány É, Gyüre T, Bozsik G, Bereczki D, Ertsey C. Tricyclic antidepressant therapy in headache. Neuropsychopharmacol. Hung. 2015 Dec; 17 (4): 177-82.Salmito MC, Duarte JA, Morganti LO, Brandao PV, Nakao BH, Villa TR, Ganança FF. Prophylactic treatment of vestibular migraine. Braz. J. Otorhinolaryngol. 2016 Jun 2. pii: S 1808-8694(16)30103-3.Salmito MC, Duarte JA, Morganti LO, Brandao PV, Nakao BH, Villa TR, Ganança FF. Prophylactic treatment of vestibular migraine. Braz. J. Otorhinolaryngol. 2016 Jun 2. pii: S 1808-8694(16)30103-3.Update on Current Care Guideline: Migraine. Duo-decim. 2015; 131 (19): 1823-5.Update on Current Care Guideline: Migraine. Duo-decim. 2015; 131 (19): 1823-5.Nagata E. Antidepressants in migraine prophylaxis. Brain Nerve. 2009 Oct; 61 (10): 1131-4.Nagata E. Antidepressants in migraine prophylaxis. Brain Nerve. 2009 Oct; 61 (10): 1131-4.Amelin AV, Skoromets AA, Korenko LA, Tumelevich BCh, Gonchar MA. [A comparative efficiency of amitriptyline, fluoxetine and maprotiline in prevention of migraine in attack-free period]. Zh. Nevrol. Psikhiatr. Im SS Korsakova. 2000; 100 (8): 20-3.Amelin AV, Skoromets AA, Korenko LA, Tumelevich BCh, Gonchar MA. [A comparative efficiency of amitriptyline, fluoxetine and maprotiline in prevention of migraine in attack-free period]. Zh. Nevrol. Psikhiatr. Im SS Korsakova. 2000; 100 (8): 20-3.d'Amato CC, Pizza V, Marmolo T, Giordano E, Alfano V, Nasta A. Fluoxetine for migraine prophylaxis: a double-blind trial. Headache. 1999Nov-Dec; 39 (10): 716-9.d'Amato CC, Pizza V, Marmolo T, Giordano E, Alfano V, Nasta A. Fluoxetine for migraine prophylaxis: a double-blind trial. Headache. 1999Nov-Dec; 39 (10): 716-9.Krymchantowski AV, Silva MT, Barbosa JS, Alves LA. Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: a double-blind study. Headache. 2002 Jun; 42 (6): 510-4.Krymchantowski AV, Silva MT, Barbosa JS, Alves LA. Amitriptyline versus amitriptyline combined with fluoxetine in the preventative treatment of transformed migraine: a double-blind study. Headache. 2002 Jun; 42 (6): 510-4.Tariaci S. Escitalopram and venlafaxine for the prophylaxis of migraine headache without mood disorders. Clin. Neuropharmacol. 2009 Sep-Oct; 32 (5): 254-8.Tariaci S. Escitalopram and venlafaxine for the prophylaxis of migraine headache without mood disorders. Clin. Neuropharmacol. 2009 Sep-Oct; 32 (5): 254-8.Adelman LC, Adelman JU, Von Seggern R, Mannix LK. Venlafaxine extended release (XR) for the prophylaxis of migraine and tension-type headache: A retrospective study in a clinical setting. Headache. 2000 Jul-Aug; 40 (7): 572-80.Adelman LC, Adelman JU, Von Seggern R, Mannix LK. Venlafaxine extended release (XR) for the prophylaxis of migraine and tension-type headache: A retrospective study in a clinical setting. Headache. 2000 Jul-Aug; 40 (7): 572-80.Ozyalcin SN, Talu GK, Kiziltan E, Yucel B, Ertas M, Disci R. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache. 2005 Feb; 45 (2): 144-52.Ozyalcin SN, Talu GK, Kiziltan E, Yucel B, Ertas M, Disci R. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache. 2005 Feb; 45 (2): 144-52.Латышева Н. В., Филатова Е. Г. Эффективность Венлафаксина при хронической ежедневной головной боли. Лечение нервных болезней. 2008, № 1 (33) стр. 26-32.Латышева Н. В., Филатова Е. Г. Эффективность Венлафаксина при хронической ежедневной головной боли. Лечение нервных болезней. 2008, № 1 (33) стр. 26-32.Латышева Н. В. Венлафаксин в лечении хронической боли. Лечение заболеваний нервной системы. 2013; № 2 (12), с. 24-29.Латышева Н. В. Венлафаксин в лечении хронической боли. Лечение заболеваний нервной системы. 2013; № 2 (12), с. 24-29.Young WB, Bradley KC, Anjum MW, Gebeline-Myers C. Duloxetine prophylaxis for episodic migraine in persons without depression: a prospective study. Headache. 2013 Oct; 53 (9): 1430-7.Young WB, Bradley KC, Anjum MW, Gebeline-Myers C. Duloxetine prophylaxis for episodic migraine in persons without depression: a prospective study. Headache. 2013 Oct; 53 (9): 1430-7.Curone M, Tullo V, Savino M, Proietti-Cecchini A, Bussone G, D'Amico D. Outcome of patients with chronic migraine with medication overuse and depression after duloxetine: influence of coexisting obsessive compulsive disorder. Neurol. Sci. 2013 May; 34 Suppl. 1: S 175-7.Curone M, Tullo V, Savino M, Proietti-Cecchini A, Bussone G, D'Amico D. Outcome of patients with chronic migraine with medication overuse and depression after duloxetine: influence of coexisting obsessive compulsive disorder. Neurol. Sci. 2013 May; 34 Suppl. 1: S 175-7.Artemenko AR, Kurenkov AL, Nikitin SS, Filatova EG. [Duloxetine in the treatment of chronic migraine]. Zh Nevrol Psikhiatr Im S Korsakova. 2010; 110 (1): 49-54.Artemenko AR, Kurenkov AL, Nikitin SS, Filatova EG. [Duloxetine in the treatment of chronic migraine]. Zh Nevrol Psikhiatr Im S Korsakova. 2010; 110 (1): 49-54.Landy S, McGinnis J, Curlin D, Laizure SC. Selective serotonin reuptake inhibitors for migraine prophylaxis. Headache. 1999 Jan; 39 (1): 28-32.Landy S, McGinnis J, Curlin D, Laizure SC. Selective serotonin reuptake inhibitors for migraine prophylaxis. Headache. 1999 Jan; 39 (1): 28-32.Lévy E, Margolese HC. Migraine headache prophylaxis and treatment with low-dose mirtazapine. Int Clin Psychopharmacol. 2003 Sep; 18 (5): 301-3.Lévy E, Margolese HC. Migraine headache prophylaxis and treatment with low-dose mirtazapine. Int Clin Psychopharmacol. 2003 Sep; 18 (5): 301-3.Engel ER, Kudrow D, Rapoport AM. A prospective, open-label study of milnacipran in the prevention of headache in patients with episodic or chronic migraine. Neurol. Sci. 2014 Mar, 35 (3): 429-35. doi: 10.1007/s10072-013-1536-0. Epub 2013 Sep 13.Engel ER, Kudrow D, Rapoport AM. A prospective, open-label study of milnacipran in the prevention of headache in patients with episodic or chronic migraine. Neurol. Sci. 2014 Mar, 35 (3): 429-35. doi: 10.1007/s10072-013-1536-0. Epub 2013 Sep 13.Bdnk J. A comparative study of amitriptyline and fluvoxamine in migraine prophylaxis. Headache. 1994 Sep; 34 (8): 476-8.Bdnk J. A comparative study of amitriptyline and fluvoxamine in migraine prophylaxis. Headache. 1994 Sep; 34 (8): 476-8.ColucciD’Amato C, Pizza V, Marmolo T, Giordano E, Alfano V, Ruggiero A. Migraine prophylactic therapy: citalopram versus flunarizine. Headache Q. 2000. 11: 213-215.ColucciD’Amato C, Pizza V, Marmolo T, Giordano E, Alfano V, Ruggiero A. Migraine prophylactic therapy: citalopram versus flunarizine. Headache Q. 2000. 11: 213-215.Park HJ, Lee ST, Shim JY, Kim B, Hwang SH, Kim SH, Park JE, Park JH, Jung SH, Ahn JY, Chu K, Kim M. The Effect of Paroxetine on the Reduction of Migraine Frequency is Independent of Its Anxiolytic Effect. J. Clin. Neurol. 2006 Dec; 2 (4): 246-51.Park HJ, Lee ST, Shim JY, Kim B, Hwang SH, Kim SH, Park JE, Park JH, Jung SH, Ahn JY, Chu K, Kim M. The Effect of Paroxetine on the Reduction of Migraine Frequency is Independent of Its Anxiolytic Effect. J. Clin. Neurol. 2006 Dec; 2 (4): 246-51.Silberstein SD. The US Headache Consortium. Practice Parametr. Evidence-based guidelines for migraine headache (an evidence-based review). Neurology. 2000; 55: 754-762.Silberstein SD. The US Headache Consortium. Practice Parametr. Evidence-based guidelines for migraine headache (an evidence-based review). Neurology. 2000; 55: 754-762.Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine - report of an EFNS task force. Eur. J. Neurol. 2009; 16: 968-981.Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine - report of an EFNS task force. Eur. J. Neurol. 2009; 16: 968-981.Jackson JL, Cogbill E, Santana-Davila R, Eldredge C, Collier W, Gradall A, Sehgal N, Kuester J. A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache. PLoS One. 2015 Jul 14;10 (7): e0130733.Jackson JL, Cogbill E, Santana-Davila R, Eldredge C, Collier W, Gradall A, Sehgal N, Kuester J. A Comparative Effectiveness Meta-Analysis of Drugs for the Prophylaxis of Migraine Headache. PLoS One. 2015 Jul 14;10 (7): e0130733.Redrobe JP, Bourin M, Colombel MC, Baker GB. Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity. Psychopharmacology (Berl). 1998 Jul; 138 (1): 1-8.Redrobe JP, Bourin M, Colombel MC, Baker GB. Dose-dependent noradrenergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity. Psychopharmacology (Berl). 1998 Jul; 138 (1): 1-8.Макаров С. А., Чурюканов М. В., Чурюканов В. В. Антидепрессанты в лечении боли. Российский журнал боли. 2016. № 3-4 (51). с. 74-84Макаров С. А., Чурюканов М. В., Чурюканов В. В. Антидепрессанты в лечении боли. Российский журнал боли. 2016. № 3-4 (51). с. 74-84Gultekin H, Ahmedov V. Role of the opioidergic system and nitric oxide in the analgesic effect of venlafaxine. Yakugaku Zasshi. 2006 Feb;126 (2): 117-21.Gultekin H, Ahmedov V. Role of the opioidergic system and nitric oxide in the analgesic effect of venlafaxine. Yakugaku Zasshi. 2006 Feb;126 (2): 117-21.Cunningham LA. Once-daify venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR208 Study Group Ann. Clin. Psychiatry. 1997 Sep; 9 (3): 157-64.Cunningham LA. Once-daify venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR208 Study Group Ann. Clin. Psychiatry. 1997 Sep; 9 (3): 157-64.Smitherman TA, Kolivas ED, Bailey JR. Panic disorder and migraine: comorbidity, mechanisms, and clinical implications. Headache. 2013 Jan; 53 (1): 23-45.Smitherman TA, Kolivas ED, Bailey JR. Panic disorder and migraine: comorbidity, mechanisms, and clinical implications. Headache. 2013 Jan; 53 (1): 23-45.American Psychiatric Association. Practice Guideline for the Treatment of Patients with Panic Disorder, 2nd edn.Washington, DC: American Psychiatric Association; 2009.American Psychiatric Association. Practice Guideline for the Treatment of Patients with Panic Disorder, 2nd edn.Washington, DC: American Psychiatric Association; 2009.Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012; 78: 1337-1345.Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012; 78: 1337-1345.https://www.drugs.com/interactions-check.php?drug_ list = 2136-0,2296-0. Ссылка активна на 25.04.17.https://www.drugs.com/interactions-check.php?drug_ list = 2136-0,2296-0. Ссылка активна на 25.04.17.U. S. Food and Drug Administration. Information for healthcare professionals: selective serotonin reuptake inhibitors (SSRIs), selective serotonin-norepinephrine reuptake inhibitors (SNRIs), 5-hydroxy-tryptamine receptor agonists (triptans). FDA ALERT [7/2006]: Potentially life-threatening serotonin syndrome with combined use of SSRIs or SNRIs and triptan medications. July 2006, updated January 21,2010.U. S. Food and Drug Administration. Information for healthcare professionals: selective serotonin reuptake inhibitors (SSRIs), selective serotonin-norepinephrine reuptake inhibitors (SNRIs), 5-hydroxy-tryptamine receptor agonists (triptans). FDA ALERT [7/2006]: Potentially life-threatening serotonin syndrome with combined use of SSRIs or SNRIs and triptan medications. July 2006, updated January 21,2010.Osmotic Device containing Venlafaxine and an antipsychotic agent: Breverri USA n.6.572.890 (Conesco in data 3.06.2003) and 7,008.641 (Conesco in data 7.03.2006).Osmotic Device containing Venlafaxine and an antipsychotic agent: Breverri USA n.6.572.890 (Conesco in data 3.06.2003) and 7,008.641 (Conesco in data 7.03.2006).Jyotir Patel. Evaluation and Development of Osmotic drug delivery of venlafaxine Hydrochloride Tablet. Asian J. Pharm. Res. 2013; Vol. 3: Issue 2, Pg 89-97.Jyotir Patel. Evaluation and Development of Osmotic drug delivery of venlafaxine Hydrochloride Tablet. Asian J. Pharm. Res. 2013; Vol. 3: Issue 2, Pg 89-97.

The authors declare that there are no conflicts of interest present.